Speaker Profile

Executive Chairman, Illumina
Biography

Jay Flatley led Illumina as President and CEO from its early years in 1999, as CEO from 2013 to earlier this year, and now serves as Executive Chairman.  He has taken the company from $1.3 million in sales in 2000 to $2.2 billion in 2015, representing a compound annual growth rate of 64 percent.  He oversaw the company’s expansion from microarrays into next-generation sequencing with the acquisition of Solexa in 2006, and more recently from research into clinical and applied markets.  Under his leadership, Illumina has been named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010), the Fortune 100 Fastest-Growing Companies (2010 and 2011) lists, and recognition by MIT Technology Review as the World’s Smartest Company in 2014. Jay chairs the Boards of Directors for two Illumina subsidiaries, Helix and Grail. In addition to his work at Illumina, he is an Advisory Board member for UC San Diego’s Moore Cancer Center, and serves on the Boards of Directors at Coherent and Denali.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!